Status:
COMPLETED
Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19
Lead Sponsor:
Dr David DE BELS
Conditions:
Covid19
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
A) Comparing the % of change in each clearances of pro-, and anti-inflammatory mediators (cytokine, chemokines and complement) in the COVID-19 patients treated with CytoSorb as compared to the same pa...
Detailed Description
Coronavirus disease-19 (COVID-19) has emerged as a serious pandemic recently, with high mortality especially in those patients who went on to develop acute respiratory failure (around 50%), and especi...
Eligibility Criteria
Inclusion
- \- Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology-Patient COVID type L (Criteria Gattinoni -CT Scan )
Exclusion
- Patient COVID type H ( Gattinoni's Criteria -CT Scan )
- Patient's refusal or refusal of his legal representative
- HIV + AIDS
- Short life Expectancy
- Patients over 80 years of age.
- Patients under ECMO or ECCO2R
- Immunosuppression (steroids, chemotherapy…)
- Cancer
Key Trial Info
Start Date :
May 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 16 2021
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04518969
Start Date
May 3 2020
End Date
September 16 2021
Last Update
March 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Brugmann
Brussels, Belgium, 1020